Neurofibromatosis Clinical Trials
Here are the 6 most popular medical studies for Neurofibromatosis
Antioxidant
Antioxidant Therapy with N-acetylcysteine for Neurofibromatosis Type 1
This trial will study the effects of N-Acetyl Cysteine on children with neurofibromatosis type 1 who commonly suffer from cognitive, behavioral, and motor impairments with the goal of reducing these impairments.
Kinase Inhibitor
Dabrafenib + Trametinib + Hydroxychloroquine for Brain Tumor
This trial is designed to study the side effects and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with brain tumors that have progressed or returned while receiving a similar agent.
Mitogen-activated Protein Kinase (MAPK) Inhibitor
Trametinib for Pediatric Brain Tumor
This trial will study the response rate of pediatric brain tumors to oral administration of the drug trametinib. A total of 150 patients will be recruited, and the study will also explore the molecular mechanisms behind tumor development, progression and resistance to treatment.
Popular filter options for Neurofibromatosis trials
NF Clinical Trials
View 54 NF medical studies.
MEK Inhibitor
Trametinib for Juvenile Myelomonocytic Leukemia
This trial looks at how well trametinib works in treating patients with JML who have relapsed or who don't respond to treatment. Trametinib may stop tumor cell growth by blocking enzymes needed for cell growth.
Behavioral Intervention
Medication + Reading Tutoring for Learning Disabilities in Neurofibromatosis Type 1
This trial will study whether the combination of a medication and reading tutoring can help improve learning disabilities in children with Neurofibromatosis Type 1.
Photosensitizer
Photodynamic Therapy for Neurofibromatosis
This trial is testing a new treatment for neurofibromas in patients with NF1. The treatment involves using a light-activated drug (Levulan Kerastick) and red light to kill the neurofibromas. The investigators will measure how well the treatment works and how long it works for.
Virus Therapy
Vaccine Therapy for Peripheral Nerve Sheath Tumor
This trial is testing a new cancer vaccine therapy to see what side effects it has and what the best dose is. The therapy is for people with a type of cancerous tumor that can't be removed by surgery or has come back after a period of improvement.
Neurofibroma Clinical Trials
View 54 Neurofibroma medical studies.
MEK Inhibitor
Trametinib for Juvenile Myelomonocytic Leukemia
This trial looks at how well trametinib works in treating patients with JML who have relapsed or who don't respond to treatment. Trametinib may stop tumor cell growth by blocking enzymes needed for cell growth.
Behavioral Intervention
Medication + Reading Tutoring for Learning Disabilities in Neurofibromatosis Type 1
This trial will study whether the combination of a medication and reading tutoring can help improve learning disabilities in children with Neurofibromatosis Type 1.
Photosensitizer
Photodynamic Therapy for Neurofibromatosis
This trial is testing a new treatment for neurofibromas in patients with NF1. The treatment involves using a light-activated drug (Levulan Kerastick) and red light to kill the neurofibromas. The investigators will measure how well the treatment works and how long it works for.
Virus Therapy
Vaccine Therapy for Peripheral Nerve Sheath Tumor
This trial is testing a new cancer vaccine therapy to see what side effects it has and what the best dose is. The therapy is for people with a type of cancerous tumor that can't be removed by surgery or has come back after a period of improvement.
NF1 Positive Clinical Trials
View 22 NF1 positive medical studies.
Behavioral Intervention
Medication + Reading Tutoring for Learning Disabilities in Neurofibromatosis Type 1
This trial will study whether the combination of a medication and reading tutoring can help improve learning disabilities in children with Neurofibromatosis Type 1.
Photosensitizer
Photodynamic Therapy for Neurofibromatosis
This trial is testing a new treatment for neurofibromas in patients with NF1. The treatment involves using a light-activated drug (Levulan Kerastick) and red light to kill the neurofibromas. The investigators will measure how well the treatment works and how long it works for.
Kinase Inhibitor
Selumetinib for Pediatric Brain Cancer
This trial is testing a new drug to treat young patients with brain cancer that has come back or does not respond to treatment. The drug may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NF2 Positive Clinical Trials
View 8 NF2 positive medical studies.
Tyrosine Kinase Inhibitor
Crizotinib for Acoustic Neuroma
This trial will test a new drug, crizotinib, on people with Neurofibromatosis Type 2 who have a progressive vestibular schwannoma. The drug will be taken orally, continuously, for 28 days at a time, for up to 12 cycles.
Neurofibromatosis Clinical Trials With No Placebo
View 59 neurofibromatosis medical studies that do not have a placebo group.
MEK Inhibitor
Trametinib for Juvenile Myelomonocytic Leukemia
This trial looks at how well trametinib works in treating patients with JML who have relapsed or who don't respond to treatment. Trametinib may stop tumor cell growth by blocking enzymes needed for cell growth.
Photosensitizer
Photodynamic Therapy for Neurofibromatosis
This trial is testing a new treatment for neurofibromas in patients with NF1. The treatment involves using a light-activated drug (Levulan Kerastick) and red light to kill the neurofibromas. The investigators will measure how well the treatment works and how long it works for.
Virus Therapy
Vaccine Therapy for Peripheral Nerve Sheath Tumor
This trial is testing a new cancer vaccine therapy to see what side effects it has and what the best dose is. The therapy is for people with a type of cancerous tumor that can't be removed by surgery or has come back after a period of improvement.
Kinase Inhibitor
Turalio for Leukemia
This trial is testing a drug called PLX3397 to see if it can help treat certain types of cancer. Eligible participants will take the drug once daily for a 28-day cycle, and will have various tests and procedures throughout the study.
View More Neurofibromatosis Trials
See another 35 medical studies focused on Neurofibromatosis.
Frequently Asked Questions
Introduction to Neurofibromatosis
What are the top hospitals conducting Neurofibromatosis research?
When it comes to advancing research and treatment options for Neurofibromatosis, several top hospitals are making significant strides. One such institution is the National Institutes of Health (NIH) Clinical Center in Bethesda. With nine active clinical trials focusing on Neurofibromatosis and a total of 20 trials conducted over time, the NIH Clinical Center has been at the forefront of studying this complex condition since their first recorded trial in 2005. In Cincinnati, the Children's Hospital Medical Center also plays a pivotal role in Neurofibromatosis research. They currently have nine ongoing clinical trials dedicated to understanding and treating this condition, with a history of 21 completed trials dating back to 2005.
Meanwhile, in Washington D.C., researchers at Children's National Medical Center are actively engaged in eight clinical trials for Neurofibromatosis while having previously contributed to 20 studies since initiating their first trial in 2002. On the West Coast, Children's Hospital Los Angeles is conducting seven active clinical trials focused on finding new treatments for neurofibromas through innovative approaches; they have already completed thirteen successful investigations since entering into researching about this disorder from starting year as late as2009.In Philadelphia's Children's Hospital stands another powerhouse driving advancements against Neurofibromatosis with seven ongoing clinical trials and an impressive history of nineteen previous studies conducted since recording their inaugural trial backin early millennium days -in earlier dates specifically set around yearas old as2001.
These leading hospitals stand out not only for their dedication but also for paving the way towards better understanding and management strategies when it comes tonNeurofibroma-related conditions like NF1and NF2.These efforts signify hope for individuals affected by these rare genetic disorders across different regions within United States,and ultimately contribute towards improving quality life overallfor everyone globally who may find themselves impacted by these conditions.Physicians,researchers,and patients alike can rest assured that these institutions are at the forefront of bringing about positive change in the fight against Neurofibromatosis.
Which are the best cities for Neurofibromatosis clinical trials?
When it comes to Neurofibromatosis clinical trials, several cities emerge as prominent locations for cutting-edge research. With 20 active trials, Boston, Massachusetts leads the way with studies focusing on Stress and Symptom Management Program 2, dabrafenib, Selumetinib Sulfate, and other promising treatments. Following closely behind is Los Angeles, California with 18 ongoing trials investigating Lenalidomide, Mirdametinib (PD-0325901) oral capsule or dispersible tablet, Binimetinib, and more. New york City also stands out with 16 active trials exploring Lenalidomide, Trametinib, Open Label Continuous Treatment regimens among others. These cities along with Bethesda Maryland and Chicago Illinois provide individuals with Neurofibromatosis access to a diverse range of clinical trials that pave the path for advancements in treatment options and improved outcomes.
Which are the top treatments for Neurofibromatosis being explored in clinical trials?
Clinical trials for Neurofibromatosis are paving the way for potential breakthroughs in treatment. Among the top contenders is selumetinib, which has shown promise with four ongoing trials and a total of ten Neurofibromatosis studies since its introduction in 2010. Another noteworthy candidate is the Stress and Symptom Management Program 2, currently being explored in two active trials after its listing in 2017. Additionally, selumetinib sulfate and trametinib hold promising positions with two active trials each, while aminolevulinic acid demonstrates potential through one ongoing trial. These innovative treatments offer hope to patients battling this challenging condition.
What are the most recent clinical trials for Neurofibromatosis?
Exciting advancements are being made in the field of neurofibromatosis, with recent clinical trials providing hope for improved treatment options. One such trial focuses on the efficacy of a flu and total body irradiation (TBI) regimen as a potential therapy for neurofibromatosis patients. Another study explores the use of erenumab-Aooe specifically for neurofibromatosis, aiming to evaluate its effectiveness in managing symptoms. Additionally, doxycycline injection and DPCP have shown promise in early phases as potential treatments for this condition. These trials offer valuable insights into new approaches that may enhance the lives of individuals living with neurofibromatosis.
What Neurofibromatosis clinical trials were recently completed?
Recently, there have been notable advancements in clinical trials for neurofibromatosis, a genetic disorder that causes tumors to develop along nerves. One significant trial involved the investigation of a potential treatment called Selumetinib, sponsored by AstraZeneca PLC and completed in June 2021. Another noteworthy study focused on Everolimus as a therapeutic option and was conducted by the National Cancer Institute (NCI), reaching completion in February 2020. These recent clinical trials signify progress towards finding effective treatments for neurofibromatosis patients, offering hope for improved outcomes and quality of life.